COVID-19 Immune Repertoire Sequencing
Completed
- Conditions
- RDTCOVIDSARS-CoV 2Corona Virus InfectionB Cell
- Registration Number
- NCT04368143
- Lead Sponsor
- Institute of Tropical Medicine, Belgium
- Brief Summary
This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints. This will allow us to investigate T and B cell evolutions during the course of infection and recovery. The expected duration of the study is four months or the total duration of the SARS-CoV-2 circulation in Belgium (whichever is shortest).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
- laboratory confirmed COVID-19 acute infection
- be older than 18 years of age
- be hospitalized at the UZA
- willing and able to provide written informed consent by the participant or its legal representative (for instance in case of medical incapacitation)
Exclusion Criteria
- younger than 18 years old
- Ambulatory patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method provide proof-of-concept that (longitudinal) B cell repertoire mining allows identification of emerging virus specific B cell receptor variable regions. 4 months
- Secondary Outcome Measures
Name Time Method clinical and epidemiological description of UZA hospitalized COVID-19 patients at hospitalization study evolutions in B and T cell repertoires to understand COVID-19 specific immune responses fundamentally. every 7 days during hospitalization a bloodsample is taken
Trial Locations
- Locations (1)
Universitairy hospital of Antwerp
🇧🇪Antwerp, Belgium